Jazz Licenses Sumitomo’s Narcolepsy Drug for US$50 M Upfront

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 5 (Table of Contents)

Published: 7 May-2022

DOI: 10.3833/pdr.v2022.i5.2689     ISSN: 1756-7874

Section: Licensing



In an attempt to expand its sleep disorder franchise, Jazz Pharmaceuticals has agreed to in-license Sumitomo Pharma’s Phase I orexin-2 receptor agonist, DSP-0187, for the potential treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details